Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 HKD | -0.76% | +2.36% | -10.96% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
ETFs positioned on Ascletis Pharma Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +1.39% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.96% | 168M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.47% | 31.28B | |
+57.86% | 25.27B | |
-15.34% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- 1672 Stock
- Funds and ETFs Ascletis Pharma Inc.